Previous 10 | Next 10 |
LA JOLLA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Principal Investigators Leila Gobejishvili, PhD and ...
MediciNova (MNOV) to commence Phase 2b trial with MN-166 (ibudilast) in chemotherapy-induced peripheral neuropathy ((CIPN)), in collaboration with The University of Sydney, and Australasian Gastro-Intestinal Trials Group ((AGITG)).The proposed trial with ~100 subjects, will evaluate ibud...
LA JOLLA, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to initiate a multi-center, placebo-control...
LA JOLLA, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the appointment of Ms. Carolyn Beaver to its Board of Di...
LA JOLLA, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive findings from a study evaluating MN-001 (tipeluk...
Gainers: [[AMAG]] +39.4%. [[DNOW]] +9.9%. [[DTIL]] +5.5% [[MNOV]] +5.0%. [[ODT]] +4.5%.Losers: [[LOGC]] -25.1%. [[SPI]] -15.6%. [[AMBO]] -5.9%. [[NG]] -5.9%. [[cc]] -4.3%. For further details see: AMAG, ODT, SPI and NG among after-hours movers
Marinus Pharmaceuticals provides updates for pivotal epilepsy study. MediciNova reports data from MN-166 trial for peripheral neuropathy. Exact Sciences shoots up on encouraging liquid biopsy data. For further details see: Marinus Epilepsy Study, And Other News: The Good...
MediciNova tanks ([[MNOV]] -22.3%) on average volume as investors appear underwhelmed with results from a small pilot study in Australia evaluating ibuilast (MN-166) for prevention of chemotherapy-induced peripheral neuropathy ((CIPN)).16 patients with metastatic upper gastrointesti...
Gainers: Sunworks (SUNW) +301%.The Peck Company (PECK) +172%.Just Energy (JE) +77%.Polar Power (POLA) +74%.Owens & Minor (OMI) +56%.Net Element (NETE) +41%.Kaleido Biosciences (KLDO) +38%.LogicBio Therapeutics (LOGC) +33%.Exact Sciences (EXAS) +24%.Pioneer Power Solutions (PPSI)...
MediciNova (MNOV) has announced clinical findings published in Cancer Chemotherapy and Pharmacology, related to MN-166 (ibudilast) as a treatment for prevention of chemotherapy-induced peripheral neuropathy ((CIPN)).14 patients completed two cycles of chemotherapy, including on...
News, Short Squeeze, Breakout and More Instantly...
Company to rededicate efforts toward updating stakeholders on corporate vision, strategy, and ongoing activities LA JOLLA, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market o...
LA JOLLA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S....
LA JOLLA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s collaborator, Gilbert Youssef, M.D....